93 related articles for article (PubMed ID: 22574128)
1. Transcriptional coactivator Cited2 induces Bmi1 and Mel18 and controls fibroblast proliferation via Ink4a/ARF.
Kranc KR; Bamforth SD; Bragança J; Norbury C; van Lohuizen M; Bhattacharya S
Mol Cell Biol; 2003 Nov; 23(21):7658-66. PubMed ID: 14560011
[TBL] [Abstract][Full Text] [Related]
2. Bmi1 drives the formation and development of intrahepatic cholangiocarcinoma independent of Ink4A/Arf repression.
Guo J; Deng N; Xu Y; Li L; Kuang D; Li M; Li X; Xu Z; Xiang M; Xu C
Pharmacol Res; 2021 Feb; 164():105365. PubMed ID: 33307220
[TBL] [Abstract][Full Text] [Related]
3. Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma.
Badodi S; Dubuc A; Zhang X; Rosser G; Da Cunha Jaeger M; Kameda-Smith MM; Morrissy AS; Guilhamon P; Suetterlin P; Li XN; Guglielmi L; Merve A; Farooq H; Lupien M; Singh SK; Basson MA; Taylor MD; Marino S
Cell Rep; 2017 Dec; 21(10):2772-2784. PubMed ID: 29212025
[TBL] [Abstract][Full Text] [Related]
4. Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma.
Badodi S; Pomella N; Lim YM; Brandner S; Morrison G; Pollard SM; Zhang X; Zabet NR; Marino S
Neuro Oncol; 2022 Aug; 24(8):1273-1285. PubMed ID: 35213723
[TBL] [Abstract][Full Text] [Related]
5. Targeted delivery of NRASQ61R and Cre-recombinase to post-natal melanocytes induces melanoma in Ink4a/Arflox/lox mice.
VanBrocklin MW; Robinson JP; Lastwika KJ; Khoury JD; Holmen SL
Pigment Cell Melanoma Res; 2010 Aug; 23(4):531-41. PubMed ID: 20444198
[TBL] [Abstract][Full Text] [Related]
6. Menin Reduces Parvalbumin Expression and is Required for the Anti-Depressant Function of Ketamine.
Leng L; Zhuang K; Lin H; Ding J; Yang S; Yuan Z; Huang C; Chen G; Chen Z; Wang M; Wang H; Sun H; Li H; Chang H; Chen Z; Xu Q; Yuan T; Zhang J
Adv Sci (Weinh); 2024 Feb; 11(5):e2305659. PubMed ID: 38044302
[TBL] [Abstract][Full Text] [Related]
7. Microglial hexokinase 2 deficiency increases ATP generation through lipid metabolism leading to β-amyloid clearance.
Leng L; Yuan Z; Pan R; Su X; Wang H; Xue J; Zhuang K; Gao J; Chen Z; Lin H; Xie W; Li H; Chen Z; Ren K; Zhang X; Wang W; Jin ZB; Wu S; Wang X; Yuan Z; Xu H; Chow HM; Zhang J
Nat Metab; 2022 Oct; 4(10):1287-1305. PubMed ID: 36203054
[TBL] [Abstract][Full Text] [Related]
8. Bmi1 Overexpression in Mesenchymal Stem Cells Exerts Antiaging and Antiosteoporosis Effects by Inactivating p16/p19 Signaling and Inhibiting Oxidative Stress.
Chen G; Zhang Y; Yu S; Sun W; Miao D
Stem Cells; 2019 Sep; 37(9):1200-1211. PubMed ID: 30895687
[TBL] [Abstract][Full Text] [Related]
9. The Stem Cell Connection of Pituitary Tumors.
Vankelecom H; Roose H
Front Endocrinol (Lausanne); 2017; 8():339. PubMed ID: 29255445
[TBL] [Abstract][Full Text] [Related]
10. The identification of human pituitary adenoma-initiating cells.
Manoranjan B; Mahendram S; Almenawer SA; Venugopal C; McFarlane N; Hallett R; Vijayakumar T; Algird A; Murty NK; Sommer DD; Provias JP; Reddy K; Singh SK
Acta Neuropathol Commun; 2016 Nov; 4(1):125. PubMed ID: 27894339
[TBL] [Abstract][Full Text] [Related]
11. A new transgenic mouse model for conditional overexpression of the Polycomb Group protein EZH2.
Koppens MA; Tanger E; Nacerddine K; Westerman B; Song JY; van Lohuizen M
Transgenic Res; 2017 Apr; 26(2):187-196. PubMed ID: 27807665
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Bmi1 in Lymphocytes Stimulates Skeletogenesis by Improving the Osteogenic Microenvironment.
Zhou X; Dai X; Wu X; Ji J; Karaplis A; Goltzman D; Yang X; Miao D
Sci Rep; 2016 Jul; 6():29171. PubMed ID: 27373231
[TBL] [Abstract][Full Text] [Related]
13. Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs.
Hayakawa Y; Kawada M; Nishikawa H; Ochiya T; Saya H; Seimiya H; Yao R; Hayashi M; Kai C; Matsuda A; Naoe T; Ohtsu A; Okazaki T; Saji H; Sata M; Sugimura H; Sugiyama Y; Toi M; Irimura T
Cancer Sci; 2016 Feb; 107(2):189-202. PubMed ID: 26919617
[TBL] [Abstract][Full Text] [Related]
14. Animal models of pituitary neoplasia.
Lines KE; Stevenson M; Thakker RV
Mol Cell Endocrinol; 2016 Feb; 421():68-81. PubMed ID: 26320859
[TBL] [Abstract][Full Text] [Related]
15. Genetically engineered mouse models of pituitary tumors.
Cano DA; Soto-Moreno A; Leal-Cerro A
Front Oncol; 2014; 4():203. PubMed ID: 25136513
[TBL] [Abstract][Full Text] [Related]
16. GFAP-Cre-mediated transgenic activation of Bmi1 results in pituitary tumors.
Westerman BA; Blom M; Tanger E; van der Valk M; Song JY; van Santen M; Gadiot J; Cornelissen-Steijger P; Zevenhoven J; Prosser HM; Uren A; Aronica E; van Lohuizen M
PLoS One; 2012; 7(5):e35943. PubMed ID: 22574128
[TBL] [Abstract][Full Text] [Related]
17. Bmi1 is required for Hedgehog pathway-driven medulloblastoma expansion.
Michael LE; Westerman BA; Ermilov AN; Wang A; Ferris J; Liu J; Blom M; Ellison DW; van Lohuizen M; Dlugosz AA
Neoplasia; 2008 Dec; 10(12):1343-9, 5p following 1349. PubMed ID: 19048113
[TBL] [Abstract][Full Text] [Related]
18. Bmi1 promotes hepatic stem cell expansion and tumorigenicity in both Ink4a/Arf-dependent and -independent manners in mice.
Chiba T; Seki A; Aoki R; Ichikawa H; Negishi M; Miyagi S; Oguro H; Saraya A; Kamiya A; Nakauchi H; Yokosuka O; Iwama A
Hepatology; 2010 Sep; 52(3):1111-23. PubMed ID: 20648475
[TBL] [Abstract][Full Text] [Related]
19. Conditional activation of Bmi1 expression regulates self-renewal, apoptosis, and differentiation of neural stem/progenitor cells in vitro and in vivo.
Yadirgi G; Leinster V; Acquati S; Bhagat H; Shakhova O; Marino S
Stem Cells; 2011 Apr; 29(4):700-12. PubMed ID: 21305672
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
